The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Apr 2016 07:00

RNS Number : 2811U
Scancell Holdings Plc
06 April 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Reyker Nominees/Investec Wealth and Investment

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

5 April 2016

6. Date on which issuer notified:

5 April 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

16%, 17%, 18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B63D3314

35,085,706

35,085,706

49,203,353

49,203,353

18.8%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

49,203,353

18.8%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFLTSEIEIIR
Date   Source Headline
8th Oct 201210:31 amRNSNotice of Results and Share Price Movement
3rd Oct 20123:30 pmRNSChange of Advisers
10th Sep 201211:10 amRNSHolding(s) in Company
3rd Sep 20125:39 pmRNSHolding(s) in Company
23rd Aug 20127:00 amRNSHolding(s) in Company
20th Aug 20124:03 pmRNSHolding(s) in Company
20th Aug 20124:01 pmRNSMarket Update
17th Aug 20129:24 amRNSHolding(s) in Company
15th Aug 20121:12 pmRNSModitope Vaccine Technology Platform
19th Jun 20127:00 amRNSLong Term Treatment Approval
25th May 20127:00 amRNSVesting of Ichor Options
2nd May 20127:00 amRNSSCIB1 Update
17th Apr 20127:00 amRNSSCIB1 Trial Update
16th Apr 201211:34 amRNSHolding(s) in Company
13th Mar 20128:23 amRNSNotice of Investor Meeting
9th Mar 20127:00 amRNSPatent Approval
29th Feb 20123:49 pmRNSChange of Registered Office
31st Jan 20127:00 amRNSHalf Year Results
13th Dec 20114:28 pmPRNIssue of Equity
17th Nov 201111:29 amPRNHoldings in Company
4th Nov 20117:00 amPRNConfirmation of GBP2.85 million payment
25th Oct 20117:00 amPRNProgress on possible GBP2.85m payment
19th Aug 201112:25 pmPRNHolding(s) in Company
18th Aug 201111:37 amPRNAppointment of Director
17th Aug 20117:00 amPRNSCIB1: Safety Review and Dose Escalation
26th Jul 20111:01 pmPRNHolding(s) in Company
25th Jul 201112:45 pmPRNAGM & EGM Statement
30th Jun 201111:48 amPRNChange of Board Structure
30th Jun 201111:46 amPRNDevelopment of new vaccine for treating lung cancer
30th Jun 201111:44 amPRNPlacing to raise £1.73 million
30th Jun 201111:37 amPRNFinal Results
3rd Jun 20117:00 amPRNAppointment of Broker
31st Jan 20118:30 amPRNInterim Results
31st Jan 20117:00 amPRNSCIB1: Safety Review and Dose Escalation
28th Jan 20117:00 amPRNRe: SCIB1 Clinical Trial Patient Recruitment
13th Jan 20117:00 amPRNIssue of Equity
14th Dec 20102:25 pmPRNResult of AGM
14th Dec 20107:00 amPRNAGM Statement
7th Sep 201011:00 amPRNRe: ImmuneRegen Strategic Collaboration
6th Sep 20107:00 amPRNAppointment of Broker
10th Aug 20107:00 amPRNLicence Agreement with Cancer Research Technology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.